Exelixis, Inc. $EXEL Shares Acquired by Tema Etfs LLC

Tema Etfs LLC boosted its stake in Exelixis, Inc. (NASDAQ:EXEL) by 47.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 87,398 shares of the biotechnology company’s stock after purchasing an additional 28,139 shares during the quarter. Tema Etfs LLC’s holdings in Exelixis were worth $3,831,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TriaGen Wealth Management LLC acquired a new position in shares of Exelixis in the 3rd quarter valued at $2,024,000. BridgePort Financial Solutions LLC acquired a new stake in shares of Exelixis during the 3rd quarter worth $517,000. Candriam S.C.A. increased its holdings in shares of Exelixis by 18.4% during the 3rd quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock worth $28,749,000 after buying an additional 108,367 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Exelixis by 11.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock worth $172,658,000 after buying an additional 419,596 shares during the period. Finally, Allianz Asset Management GmbH raised its position in shares of Exelixis by 153.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after buying an additional 1,490,520 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insiders Place Their Bets

In other Exelixis news, EVP Dana Aftab sold 47,918 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total value of $2,132,351.00. Following the completion of the transaction, the executive vice president owned 616,106 shares in the company, valued at $27,416,717. This represents a 7.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack L. Wyszomierski sold 99,574 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the completion of the sale, the director directly owned 279,942 shares of the company’s stock, valued at $12,320,247.42. This trade represents a 26.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 362,849 shares of company stock valued at $15,917,463. Company insiders own 2.82% of the company’s stock.

Exelixis Trading Up 2.7%

Shares of Exelixis stock opened at $44.04 on Thursday. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62. The stock has a market cap of $11.44 billion, a price-to-earnings ratio of 15.90, a price-to-earnings-growth ratio of 0.96 and a beta of 0.42. The company has a fifty day moving average price of $42.70 and a 200 day moving average price of $42.05.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. The company had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company posted $0.55 earnings per share. Analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analysts Set New Price Targets

EXEL has been the subject of a number of research reports. Morgan Stanley boosted their price target on Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Stifel Nicolaus raised their price objective on Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a report on Wednesday, February 11th. Royal Bank Of Canada reduced their price objective on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research note on Monday, March 2nd. Bank of America cut Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price for the company. in a report on Monday, January 5th. Finally, Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Exelixis currently has an average rating of “Hold” and an average target price of $46.94.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.